Using Mobile Phones to Improve Adherence to Inhaled Steroids

NACompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

December 31, 2012

Primary Completion Date

November 30, 2013

Study Completion Date

November 30, 2013

Conditions
Asthma
Interventions
BEHAVIORAL

Asthma Supervision

Each participant will be provided with a spacer and a peak flow meter, and instructions on proper technique, by a member of the study team during the baseline period. They will also meet with study staff at study visits during the active treatment phase to review their adherence to daily inhaled corticosteroids and usage patterns of short acting B2-agonist medication.

BEHAVIORAL

Mobile Phone

Each participant will receive a mobile phone with talking, texting and a data plan. They will get to keep the mobile phone at the end of the study, but the talking, texting and data plan will only be active during their participation in the study.

BEHAVIORAL

Inhaled Corticosteroid Mobile Phone Application

The Inhaled Corticosteroid Mobile Phone Application will be used to provide virtual doctor supervision, immediate feedback, and positive reinforcement for taking inhaled corticosteroid medication as indicated.

BEHAVIORAL

Beta2-adrenergic agonist Mobile Phone Application

The Beta2-adrenergic agonist Mobile Phone Application will be used to track real time patterns of use of beta2-adrenergic agonist medication.

Trial Locations (1)

60612

Rush University Medical Center, Chicago

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

National Heart, Lung, and Blood Institute (NHLBI)

NIH

collaborator

GlaxoSmithKline

INDUSTRY

lead

Rush University Medical Center

OTHER